Skip to main content

Press Releases

Month Year

Month Year

May 21, 2023

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 18, 2023

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
May 5, 2023

New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline

17 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma
May 1, 2023

Sanofi Canada et Diabetes Care Community annoncent une collaboration pour soutenir le parcours de bien-être émotionnel des Canadiens et Canadiennes vivant avec le diabète
Apr 27, 2023

Sanofi completes acquisition of Provention Bio, Inc.
Apr 4, 2023

Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
Mar 23, 2023

Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
Mar 18, 2023

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
Mar 13, 2023

Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Mar 7, 2023

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Show per page

Print
Email page
RSS